CL2020001452A1 - Agonista del receptor de glucocorticoides e inmunoconjugados de este. - Google Patents
Agonista del receptor de glucocorticoides e inmunoconjugados de este.Info
- Publication number
- CL2020001452A1 CL2020001452A1 CL2020001452A CL2020001452A CL2020001452A1 CL 2020001452 A1 CL2020001452 A1 CL 2020001452A1 CL 2020001452 A CL2020001452 A CL 2020001452A CL 2020001452 A CL2020001452 A CL 2020001452A CL 2020001452 A1 CL2020001452 A1 CL 2020001452A1
- Authority
- CL
- Chile
- Prior art keywords
- immunoconjugates
- glucocorticoid receptor
- receptor agonist
- receptor agonists
- glucocorticoid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
En la presente se proporcionan inmunoconjugados de agonistas del receptor de glucocorticoides, agonistas del receptor de glucocorticoides y métodos para usarlos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762593776P | 2017-12-01 | 2017-12-01 | |
US201762595054P | 2017-12-05 | 2017-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020001452A1 true CL2020001452A1 (es) | 2020-09-11 |
Family
ID=65010803
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020001452A CL2020001452A1 (es) | 2017-12-01 | 2020-05-29 | Agonista del receptor de glucocorticoides e inmunoconjugados de este. |
CL2021001075A CL2021001075A1 (es) | 2017-12-01 | 2021-04-26 | Agonista del receptor de glucocorticoides e inmunoconjugados de este solicitud divisional de 202001452) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021001075A CL2021001075A1 (es) | 2017-12-01 | 2021-04-26 | Agonista del receptor de glucocorticoides e inmunoconjugados de este solicitud divisional de 202001452) |
Country Status (34)
Country | Link |
---|---|
US (2) | US10772970B2 (es) |
EP (2) | EP3884962A1 (es) |
JP (2) | JP6813712B2 (es) |
KR (1) | KR20200095477A (es) |
CN (1) | CN111417410B (es) |
AU (1) | AU2018374634A1 (es) |
BR (1) | BR112020010694A2 (es) |
CA (1) | CA3082356A1 (es) |
CL (2) | CL2020001452A1 (es) |
CO (1) | CO2020006446A2 (es) |
CR (1) | CR20200239A (es) |
CY (1) | CY1124230T1 (es) |
DK (1) | DK3658192T3 (es) |
DO (1) | DOP2020000116A (es) |
EC (1) | ECSP20029001A (es) |
ES (1) | ES2877659T3 (es) |
HR (1) | HRP20210917T1 (es) |
HU (1) | HUE054428T2 (es) |
IL (1) | IL274651B (es) |
LT (1) | LT3658192T (es) |
MA (1) | MA49796A (es) |
MX (1) | MX2020005583A (es) |
PE (1) | PE20201286A1 (es) |
PL (1) | PL3658192T3 (es) |
PT (1) | PT3658192T (es) |
RS (1) | RS61994B1 (es) |
RU (1) | RU2020117698A (es) |
SG (1) | SG11202004867WA (es) |
SI (1) | SI3658192T1 (es) |
TW (1) | TWI803542B (es) |
UA (1) | UA126595C2 (es) |
UY (1) | UY37991A (es) |
WO (1) | WO2019106609A1 (es) |
ZA (1) | ZA202003325B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20201286A1 (es) * | 2017-12-01 | 2020-11-24 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados de este |
AU2021261386A1 (en) * | 2020-04-22 | 2022-11-24 | Immunext, Inc. | Anti-human vista antibodies and use thereof |
CA3207416A1 (en) * | 2021-02-04 | 2022-08-11 | Lingjian ZHU | Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine |
TW202304462A (zh) * | 2021-03-23 | 2023-02-01 | 美商美國禮來大藥廠 | 糖皮質素受體激動劑 |
AR125079A1 (es) | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Agonistas de receptores de glucocorticoides sustituidos con carboxi |
WO2022268176A1 (zh) * | 2021-06-24 | 2022-12-29 | 江苏先声药业有限公司 | 甾体类化合物、其药物组合物及其应用 |
WO2023025248A1 (zh) * | 2021-08-26 | 2023-03-02 | 映恩生物制药(苏州)有限公司 | 一种甾体化合物及其缀合物 |
TW202327620A (zh) * | 2021-09-14 | 2023-07-16 | 大陸商映恩生物製藥(蘇州)有限公司 | 一種抗炎症的化合物及其用途 |
TW202340252A (zh) * | 2022-01-29 | 2023-10-16 | 大陸商上海盛迪醫藥有限公司 | 糖皮質激素的藥物偶聯物 |
WO2024020164A2 (en) | 2022-07-21 | 2024-01-25 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
WO2024064779A1 (en) * | 2022-09-22 | 2024-03-28 | Eli Lilly And Company | Glucocorticoid receptor agonists |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3126375A (en) | 1964-03-24 | Chioacyl | ||
GB933868A (en) | 1958-12-08 | 1963-08-14 | American Cyanamid Co | Process for fluorinating steroids |
IT1057859B (it) | 1972-04-28 | 1982-03-30 | Sigma Tao Ind Farmaceutiche Sp | Perivato del triamoinolone |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5010176A (en) | 1988-11-10 | 1991-04-23 | Eli Lilly And Company | Antibody-drug conjugates |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
NZ265054A (en) | 1993-04-02 | 1997-08-22 | Byk Gulden Lomberg Chem Fab | 16-hydroxy prednisolone cyclohexanecarboxaldehyde acetal derivatives |
WO1994025478A1 (en) | 1993-04-29 | 1994-11-10 | Instytut Farmaceutyczny | 16α,17α-ACETAL GLUCOCORTICOSTEROIDAL DERIVATIVES |
EP0749438B1 (de) | 1994-03-09 | 2000-12-13 | Byk Gulden Lomberg Chemische Fabrik GmbH | Neue silylverbindungen und ihre verwendung |
JP2749778B2 (ja) | 1994-09-05 | 1998-05-13 | 日清食品株式会社 | トリアムシノロン誘導体 |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US5792758A (en) | 1995-12-08 | 1998-08-11 | G. D. Searle & Co. | Steroid nitrite ester derivatives useful as anti-inflammatory drugs |
BRPI9715219B8 (pt) | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Vetor recombinante de expressão, e célula hospedeira procariótica. |
US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
DE19635498A1 (de) | 1996-09-03 | 1998-03-26 | Byk Gulden Lomberg Chem Fab | Verfahren zur Epimerenanreicherung |
AU3703900A (en) | 1999-02-24 | 2000-09-14 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
DE10055820C1 (de) | 2000-11-10 | 2002-07-25 | Byk Gulden Lomberg Chem Fab | Verfahren zur Herstellung eines Glucocorticoids |
EA006231B1 (ru) | 2000-11-10 | 2005-10-27 | Алтана Фарма Аг | Способ получения 16,17-[(циклогексилметилен)бис(окси)]-11,21-дигидроксипрегна-1,4-диен-3,20-диона или его 21-изобутирата транскетализацией |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
ES2516041T3 (es) | 2001-10-10 | 2014-10-30 | Ratiopharm Gmbh | Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH) |
CN1585778A (zh) | 2001-11-12 | 2005-02-23 | 默克专利有限公司 | 修饰的抗-TNFα抗体 |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
WO2004017904A2 (en) | 2002-08-23 | 2004-03-04 | The Mclean Hospital Corporation | Corticosteroid conjugates and uses thereof |
EP1567113A4 (en) | 2002-10-24 | 2006-11-08 | G & R Pharmaceuticals Llc | ANTIFUNGAL PREPARATIONS |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
AR042461A1 (es) | 2002-12-13 | 2005-06-22 | Neurogen Corp | Analogos 2-sustituidos de quinazolin-4-il - amina. composiciones farmaceuticas |
AU2004207003A1 (en) | 2003-01-30 | 2004-08-12 | Medimmune, Llc | Anti-integrin alphanubeta3 antibody formulations and uses thereof |
MY143936A (en) | 2003-03-27 | 2011-07-29 | Nycomed Gmbh | Process for preparing crystalline ciclesonide with defined particle size |
WO2005044759A2 (en) | 2003-08-14 | 2005-05-19 | Sun Pharmaceutical Industries Limited | Acetalization process for preparation of steroid compounds |
US8371292B2 (en) | 2003-09-16 | 2013-02-12 | Nycomed Gmbh | Use of ciclesonide for the treatment of respiratory diseases |
WO2005028495A1 (en) | 2003-09-24 | 2005-03-31 | Glaxo Group Limited | Anti-inflammatory glucocorticoids |
EP1680073B1 (en) | 2003-10-21 | 2013-01-02 | IGF Oncology, LLC | Compounds and method for treating cancer |
CN100455582C (zh) | 2003-11-13 | 2009-01-28 | 霍夫曼-拉罗奇有限公司 | 羟烷基取代的吡啶并-7-嘧啶-7-酮 |
EP1697370B1 (en) | 2003-12-19 | 2007-04-25 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
WO2005063777A1 (en) | 2003-12-23 | 2005-07-14 | Corus Pharma | Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation |
EP1729724A4 (en) | 2003-12-31 | 2008-07-23 | Cydex Inc | INHALATION FORMULATION WITH SULFOALKYL ETHER GAMMA CYCLODEXTRIN AND CORTICOSTEROID |
GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
US7837980B2 (en) | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
EP1685161A1 (en) | 2004-08-30 | 2006-08-02 | Lonza Biologics plc | Affinity- plus ion exchange-chromatography for purifying antibodies |
RS57636B1 (sr) | 2004-09-03 | 2018-11-30 | Genentech Inc | Humanizovani anti-beta7 antagonisti i njihova upotreba |
JP2008512428A (ja) | 2004-09-10 | 2008-04-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクレソニドとSykインヒビターとの組合せ物並びにその使用方法 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス, インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
WO2006097458A1 (en) | 2005-03-15 | 2006-09-21 | Nycomed Gmbh | Novel combination |
WO2006110593A2 (en) | 2005-04-07 | 2006-10-19 | Macrogenics, Inc. | Biological targets for the diagnosis, treatment and prevention of cancer |
EP1712220A1 (en) | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
WO2006135479A2 (en) | 2005-05-10 | 2006-12-21 | Angiotech International Ag | Anti-scarring agents, therapeutic compositions, and use thereof |
WO2006138212A1 (en) | 2005-06-14 | 2006-12-28 | Gilead Sciences, Inc. | SUBSTITUTED PHENYLPHOSPHATES AS MUTUAL PRODRUGS OF STEROIDS AND β -AGONISTS FOR THE TREATMENT OF PULMONARY INFLAMMATION AND BRONCHOCONSTRICTION |
PL1912677T3 (pl) | 2005-06-20 | 2014-03-31 | Psma Dev Company L L C | Koniugaty przeciwciało PSMA-lek |
WO2007054974A2 (en) | 2005-09-28 | 2007-05-18 | Arch Pharmalab Limited | A green chemistry process for the preparation of pregnadiene esters |
WO2007117685A2 (en) | 2006-04-07 | 2007-10-18 | Nektar Therapeutics Al, Corporation | Conjugates of an anti-tnf-alpha antibody |
WO2008015696A2 (en) | 2006-05-23 | 2008-02-07 | Cadila Healthcare Limited | Process for preparing ciclesonide |
CA2652945C (en) | 2006-05-30 | 2015-06-02 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
JP2010503722A (ja) | 2006-09-19 | 2010-02-04 | シプラ・リミテッド | シクレソニドとその結晶変異体の調製方法 |
WO2008052350A1 (en) | 2006-11-03 | 2008-05-08 | Qlt Inc. | Photodynamic therapy for the treatment of hidradenitis suppurativa |
NO331891B1 (no) | 2007-03-20 | 2012-04-30 | Clavis Pharma Asa | Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS |
UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
EP2173169B1 (en) | 2007-06-28 | 2014-05-21 | CyDex Pharmaceuticals, Inc. | Nasal delivery of aqueous corticosteroid solutions |
MX2010005861A (es) | 2007-11-30 | 2010-06-11 | Pfizer Ltd | Agonistas novedosos de los receptores de glucocorticoides. |
CL2008003802A1 (es) | 2007-12-21 | 2010-02-19 | Schering Corp | Compuestos derivados de tioeteres c-21, agonistas del receptor de glucocorticoide; composicion farmaceutica; y uso para el tratamiento o profilaxis de una enfermedad o afeccion inmune, autoinmune o inflamatoria, tales como artritis reumatoide y esclerosis multiple. |
JP2011507878A (ja) | 2007-12-21 | 2011-03-10 | シェーリング コーポレイション | C20−c21置換グルココルチコイド受容体アゴニスト |
DK3153526T3 (da) | 2008-01-31 | 2020-12-14 | Inst Nat Sante Rech Med | Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler |
RU2010133722A (ru) | 2008-02-27 | 2012-04-10 | Астразенека Аб (Se) | 16-альфа, 17-альфа-ацетальглюкокортикостероидные производные и их применение |
PT2262823E (pt) | 2008-03-13 | 2013-03-05 | Farmabios Spa | Processo para a preparação de derivados de pregnano |
WO2009152171A1 (en) | 2008-06-10 | 2009-12-17 | Gilead Sciences, Inc. | Corticosteroid linked beta-agonist compounds for use in therapy |
BRPI0914789A2 (pt) | 2008-06-16 | 2015-10-20 | Immunogen Inc | efeitos sinérgicos |
BRPI0914629A2 (pt) | 2008-06-24 | 2019-09-24 | Irm Llc | compostos e métodos para a modulação de receptores acoplados à proteína g |
US20100120733A1 (en) | 2008-11-07 | 2010-05-13 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
AU2009322236B2 (en) | 2008-12-04 | 2013-11-07 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
KR101940059B1 (ko) | 2008-12-19 | 2019-01-18 | 마크로제닉스, 인크. | 공유결합형 디아바디 및 이의 용도 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
JP5412622B2 (ja) | 2009-03-09 | 2014-02-12 | 三笠製薬株式会社 | ステロイド化合物 |
WO2010126953A1 (en) | 2009-04-29 | 2010-11-04 | Gilead Sciences, Inc. | Corticosteroid linked beta-agonist compounds for use in therapy |
WO2010132743A1 (en) | 2009-05-15 | 2010-11-18 | Gilead Sciences, Inc. | Corticosteroid beta-agonist compounds for use in therapy |
JP2012528140A (ja) | 2009-05-29 | 2012-11-12 | ファイザー・リミテッド | 新規なグルココルチコイド受容体アゴニスト |
GB0917044D0 (en) | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
CN102665757A (zh) | 2009-12-09 | 2012-09-12 | 免疫医疗公司 | 通过双特异性抗体预靶向的用于细胞毒性药物的递送系统 |
WO2011081937A1 (en) | 2009-12-15 | 2011-07-07 | Gilead Sciences, Inc. | Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy |
CN102167741B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗TNF-α单克隆抗体、其制备方法及用途 |
CA2795734A1 (en) | 2010-04-07 | 2011-10-13 | Abbvie Inc. | Tnf-.alpha. binding proteins |
ES2617777T5 (es) | 2010-04-23 | 2022-10-13 | Hoffmann La Roche | Producción de proteínas heteromultiméricas |
CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
ES2685607T3 (es) | 2010-06-03 | 2018-10-10 | Abbvie Biotechnology Ltd | Usos y composiciones para el tratamiento de la hidradenitis supurativa (HS) |
JP2013539353A (ja) | 2010-06-24 | 2013-10-24 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
AU2011305567A1 (en) | 2010-09-22 | 2013-05-02 | Map Pharmaceuticals, Inc. | Corticosteroid particles and method of production |
AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
WO2012082947A1 (en) | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
WO2012089247A1 (en) | 2010-12-29 | 2012-07-05 | Nokia Siemens Networks Oy | A method and apparatus for transmitting an identity |
CN106039306A (zh) | 2011-03-30 | 2016-10-26 | 埃博灵克斯股份有限公司 | 使用针对TNFα的单结构域抗体治疗免疫病症的方法 |
BR112014009810A2 (pt) | 2011-10-24 | 2017-04-25 | Abbvie Inc | imunoligantes biespecíficos dirigidos contra tnf e il-17 |
CN104093739A (zh) | 2011-10-24 | 2014-10-08 | 艾伯维公司 | 针对tnf的免疫结合剂 |
US20130115269A1 (en) | 2011-11-04 | 2013-05-09 | Henry John Smith | Anti-tumor necrosis factor alpha (TNF-a) antibody used as a targeting agent to treat arthritis and other diseases |
EP2791171A1 (en) | 2011-12-16 | 2014-10-22 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
US9109005B2 (en) | 2012-02-23 | 2015-08-18 | Boehringer Ingelheim International Gmbh | Method for manufacturing of ciclesonide |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
EP2647627A1 (en) | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
CN103421075B (zh) | 2012-05-16 | 2017-07-28 | 上海特化医药科技有限公司 | 孕烷衍生物16,17‑缩醛(酮)的制备方法 |
US20150158943A1 (en) | 2012-06-01 | 2015-06-11 | Momenta Pharmaceuticals, Inc. | Methods related to adalimumab |
WO2014058389A1 (en) | 2012-10-12 | 2014-04-17 | Agency For Science, Technology And Research | Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics |
ES2701076T3 (es) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células |
ES2819573T3 (es) | 2012-12-13 | 2021-04-16 | Immunomedics Inc | Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A |
ES2706757T3 (es) | 2012-12-21 | 2019-04-01 | Boehringer Ingelheim Vetmedica Gmbh | Formulación farmacéutica que comprende ciclesonida |
CA2898676A1 (en) | 2013-03-15 | 2014-09-25 | Abbvie, Inc. | Improved tnf binding proteins |
EP3049443A4 (en) | 2013-09-27 | 2017-04-05 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
EP3125943A4 (en) | 2014-04-04 | 2017-12-06 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
CA2948013A1 (en) | 2014-06-30 | 2016-01-07 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2) |
EP3193829B1 (en) | 2014-09-19 | 2021-12-08 | Oxular Limited | Ophthalmic drug compositions |
EP3250211B1 (en) | 2015-01-30 | 2021-12-22 | Coral Drugs Pvt. Ltd. | Novel process for preparation of glucocorticoid steroids |
JP2016190798A (ja) | 2015-03-31 | 2016-11-10 | 三笠製薬株式会社 | アレルギー性鼻炎治療用局所点鼻薬 |
EP3307749A4 (en) | 2015-06-15 | 2019-06-19 | Hangzhou Dac Biotech Co., Ltd | HYDROPHILIC LINKER FOR CONJUGATION |
CN107921144B (zh) | 2015-06-20 | 2023-11-28 | 杭州多禧生物科技有限公司 | 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物 |
WO2015155753A2 (en) | 2015-08-10 | 2015-10-15 | Suzhou M-Conj Biotech Co., Ltd | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
JP2017066075A (ja) | 2015-09-30 | 2017-04-06 | 三笠製薬株式会社 | リウマチ治療薬 |
CA3025377A1 (en) | 2016-06-02 | 2017-12-07 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
JP6767796B2 (ja) | 2016-07-08 | 2020-10-14 | 株式会社日立情報通信エンジニアリング | 通話管理システム及びその音声認識制御方法 |
JP7330101B2 (ja) | 2016-11-08 | 2023-08-21 | レゲネロン ファーマシューティカルス,インコーポレーテッド | ステロイド及びそのタンパク質コンジュゲート |
PE20201286A1 (es) * | 2017-12-01 | 2020-11-24 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados de este |
-
2018
- 2018-11-29 PE PE2020000608A patent/PE20201286A1/es unknown
- 2018-11-29 BR BR112020010694-1A patent/BR112020010694A2/pt unknown
- 2018-11-29 MX MX2020005583A patent/MX2020005583A/es unknown
- 2018-11-29 RU RU2020117698A patent/RU2020117698A/ru unknown
- 2018-11-29 EP EP21162680.9A patent/EP3884962A1/en active Pending
- 2018-11-29 CA CA3082356A patent/CA3082356A1/en active Pending
- 2018-11-29 SI SI201830305T patent/SI3658192T1/sl unknown
- 2018-11-29 KR KR1020207015633A patent/KR20200095477A/ko active Search and Examination
- 2018-11-29 CN CN201880077432.9A patent/CN111417410B/zh active Active
- 2018-11-29 CR CR20200239A patent/CR20200239A/es unknown
- 2018-11-29 RS RS20210761A patent/RS61994B1/sr unknown
- 2018-11-29 JP JP2020512845A patent/JP6813712B2/ja active Active
- 2018-11-29 MA MA049796A patent/MA49796A/fr unknown
- 2018-11-29 EP EP18833113.6A patent/EP3658192B1/en active Active
- 2018-11-29 HU HUE18833113A patent/HUE054428T2/hu unknown
- 2018-11-29 TW TW107142830A patent/TWI803542B/zh active
- 2018-11-29 DK DK18833113.6T patent/DK3658192T3/da active
- 2018-11-29 PL PL18833113T patent/PL3658192T3/pl unknown
- 2018-11-29 SG SG11202004867WA patent/SG11202004867WA/en unknown
- 2018-11-29 US US16/204,825 patent/US10772970B2/en active Active
- 2018-11-29 ES ES18833113T patent/ES2877659T3/es active Active
- 2018-11-29 WO PCT/IB2018/059482 patent/WO2019106609A1/en unknown
- 2018-11-29 UA UAA202003245A patent/UA126595C2/uk unknown
- 2018-11-29 LT LTEP18833113.6T patent/LT3658192T/lt unknown
- 2018-11-29 AU AU2018374634A patent/AU2018374634A1/en active Pending
- 2018-11-29 PT PT188331136T patent/PT3658192T/pt unknown
- 2018-12-03 UY UY0001037991A patent/UY37991A/es not_active Application Discontinuation
-
2020
- 2020-05-13 IL IL274651A patent/IL274651B/en active IP Right Grant
- 2020-05-27 CO CONC2020/0006446A patent/CO2020006446A2/es unknown
- 2020-05-29 CL CL2020001452A patent/CL2020001452A1/es unknown
- 2020-05-29 EC ECSENADI202029001A patent/ECSP20029001A/es unknown
- 2020-06-03 ZA ZA2020/03325A patent/ZA202003325B/en unknown
- 2020-06-15 DO DO2020000116A patent/DOP2020000116A/es unknown
- 2020-07-31 US US16/945,069 patent/US20210015938A1/en not_active Abandoned
- 2020-12-17 JP JP2020209056A patent/JP2021054845A/ja active Pending
-
2021
- 2021-04-26 CL CL2021001075A patent/CL2021001075A1/es unknown
- 2021-06-09 HR HRP20210917TT patent/HRP20210917T1/hr unknown
- 2021-06-18 CY CY20211100547T patent/CY1124230T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020001452A1 (es) | Agonista del receptor de glucocorticoides e inmunoconjugados de este. | |
ECSP18094857A (es) | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo | |
ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
DK3596053T3 (da) | Farnesoid-x-receptoragonister og anvendelser deraf | |
CL2021001521A1 (es) | Compuesto agonista de receptor thrb y método de preparación y uso del mismo | |
ECSP17063327A (es) | Receptores de antígeno quiméricos antidll3 y métodos de uso | |
ECSP18008905A (es) | Tricíclicos sustituidos y método para usarlos. | |
CL2017001288A1 (es) | Agonistas parciales del receptor de insulina | |
CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
CR20170131A (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CR20160362A (es) | Anticuerpos anti-jagged1 y metodos de uso | |
MX2019004690A (es) | Constructos de anticuerpos. | |
BR112018008960A2 (pt) | estrutura de relatório de formação de feixe | |
ECSP21001786A (es) | Degradadores selectivos del receptor de estrógeno | |
CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
CL2023002809A1 (es) | Agonistas del receptor de glucocorticoides | |
ECSDI17073701S (es) | Dispositivo para peluqueria | |
ECSDI17073700S (es) | Dispositivo para peluqueria | |
BR112018014940A2 (pt) | combinação de herbicida | |
AR112602A1 (es) | ANTICUERPOS ANTI-TrkB | |
AR113867A1 (es) | Agonista del receptor de glucocorticoides e inmunoconjugados de este | |
BR112019005725A2 (pt) | ajuste de dose | |
CR20160585A (es) | Polipéptidos receptores formulados y métodos relacionados | |
TWD174146S (zh) | 光學裝置 |